News – Page 854 – Endpoints News

SIGN UP

Drug approvals: FDA publishes dataset of CDER approvals since 1985

6 years ago

Animal health vet Juergen Horn makes new antibody play for pets, raking $15M in Series A haul

6 years ago

As coronavirus outbreak reaches 'tipping point,' GSK lends adjuvant tech to Chinese partner armed with preclinical ...

6 years ago

The fourth CGRP migraine drug is here. Time for Lundbeck to prove it's worth $2B

6 years ago

Esperion's goldilocks cholesterol fighter wins FDA approval — will its 'traditional' pricing approach spur ...

6 years ago

A space odyssey for new antibiotics: MIT's machine learning approach

6 years ago

Genfit delays high-stakes PhIII NASH readout; Bristol-Myers grabs first Opdivo OK in esophageal cancer

6 years ago

Gilead loses two more patent challenges on HIV pill, setting up courtroom fight in Delaware

6 years ago

Bankrupt antibiotics maker Aradigm turns to old partner/investor for final $3M fire sale

6 years ago

DBV's peanut prevention patch approaches key stage of approval process

6 years ago

Antonio Gualberto starts post-Kura career at Eisai subsidiary H3; eFFECTOR co-founder Siegfried Reich jumps to ...

6 years ago

Say goodbye to Tocagen, struggling brain cancer biotech to reverse merge with Forte Biosciences

6 years ago

Speedy review and no adcomm for BioMarin's pioneering hemophilia gene therapy

6 years ago

Gene therapy pioneer Kathy High has left Spark after completing $4.3B union with Roche

6 years ago

Pharmacogenetics: FDA releases table of gene-drug interactions

6 years ago

Heron's Groundhog Day; Vifor forms JV with Fresenius Kabi in China

6 years ago

Fresh off $100M round, GV-backed real-world data startup woos Duke researcher as CMO

6 years ago

Merck loses its chief digital officer, spotlighting talent hunt for the hottest title in Big Pharma

6 years ago

Don't let AbbVie fool FTC with an easy divestiture, plead critics in latest attack on $63B Allergan buyout

6 years ago

Austedo, Teva's bright spot as it executes turnaround, fails two Tourette's trials

6 years ago

Armed with a batch of positive biomarker data, a rare disease player reaps $88M for the next big push in the clinic

6 years ago

FDA consolidates nonclinical immunotoxicity evaluation guidance

6 years ago

Eli Lilly vet Kerry Blanchard takes the helm at one of China's top dealmakers, steering toward first approvals

6 years ago

TCR-focused Immatics adds another marquee name to its list of partners: GSK

6 years ago

First page Previous page 851 852 853854855 856 857 Next page Last page